The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail

Palexia SR 100 mg prolonged-release tablets

100 milligram(s) Prolonged-release tablet

Grunenthal Pharma LtdPA2242/012/005

Main Information

Trade NamePalexia SR 100 mg prolonged-release tablets
Active SubstancesTapentadol hydrochloride
Strength100 milligram(s)
Dosage FormProlonged-release tablet
Licence HolderGrunenthal Pharma Ltd
Licence NumberPA2242/012/005

Group Information

ATC CodeN02AX Other opioids
N02AX06 tapentadol


Licence Issued21/12/2010
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of LicenceThis product contains a substance listed in schedule 2 to the Misuse of Drugs Regulations 2017.
Marketing StatusMarketed


Summary of Product CharacteristicsPDF Version
Package LeafletNo document available
Public Assessment ReportNo document available
« Back